Kidney | Melanoma, skin, Phase II

A Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 Experienced

Volunteers
Health Professionals

What is the purpose of this trial?

This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Harriet Kluger

harriet.kluger@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Harriet Kluger, MD
Harvey and Kate Cushing Professor of Medicine (Oncology) and of Dermatology; Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Vice Chair for Collaborative Research, Internal Medicine; Chief, Division of Skin and Kidney Cancer; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology

Sub-Investigators

Last Updated
07/28/2024
Study HIC
#2000030391